Intensive Studies for Recertification: Pediatric Pharmacy (Cert # L209097)

ACPE Numbers: 
0204-0000-19-233-H01-P
0204-0000-19-256-H01-P
0204-0000-19-296-H01-P

Content Release Date: 02/05/2020
Expiration Date: 02/02/2021
Activity Type: Application-based
CE Credits: 4.0 hours

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities were recorded during a live educational event on December 9-11, 2019 at the Midyear Clinical Meeting in Las Vegas, Nevada. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Anticoagulation, especially in pediatric patients
  • Managing the impact of drug therapy on neurodevelopmental outcomes
  • Pediatric pharmacotherapy
  • Using ketamine in critically ill patients

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pediatric pharmacy.

The Pediatric Pharmacy Intensive Study Recertification Package consists of 3 activities (see table below) recorded during a live educational event on December 9-11, 2019 at the Midyear Clinical Meeting in Las Vegas, Nevada, and provides up to 4.0 hours of continuing pharmacy education and/or recertification credit.  

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.  For pharmacists who maintain more than one certification, one of the activities is approved for multiple specialties (see table below).

Recertification Credit*

Board certified pharmacists are eligible to receive up to 4.0 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Module

ACPE Number

Credit Hours

Specialty

*Assessment Pass Point

The Use of Ketamine in Critically Ill Adults and Children

0204-0000-19-233-H01-P

1.5

BCPPS, BCCCP,  BCPS

73%

Bad to the Brain: Impact of Neonatal Medication Use on the Developing Brain

0204-0000-19-256-H01-P

1.0

BCPPS

66%

Is Pediatric Anticoagulation Experiencing a Paradigm Shift?

0204-0000-19-296-H01-P

1.5

BCPPS

75%

Learning Objectives

The Use of Ketamine in Critically Ill Adults and Children
0204-0000-19-233-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Apply recent literature and logistical considerations in the use of ketamine in cases involving critically ill adult and pediatric patients.
  • Develop strategies for the effective use of ketamine for pain management and attenuation or reversal of opioid tolerance in patients in the emergency department or intensive care unit.
  • Explain the role of ketamine in adult and pediatric patients with status epilepticus.
  • Compare and contrast the use of ketamine for pain management, attenuation of opioid tolerance, and treatment of status epilepticus, between adult and pediatric patients.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Bad to the Brain: Impact of Neonatal Medication Use on the Developing Brain
0204-0000-19-256-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Categorize sedative, analgesic, and anesthetic agents associated with negative or positive effects on neurodevelopment when used during the neonatal period.
  • Compare and contrast neurodevelopmental outcomes from the use of phenobarbital, levetiracetam, or other antiepileptic agents for treatment of neonatal seizures.
  • Evaluate recent literature addressing the effects of corticosteroid use during the neonatal period on neurodevelopmental outcomes.
  • Develop a list of medications used in the neonatal intensive care unit (NICU) for which additional long-term neurodevelopmental follow-up data are needed to ensure safety.

This activity is approved for Board Certified Pediatric Pharmacist (BCPPS) recertification credit.

Is Pediatric Anticoagulation Experiencing a Paradigm Shift?
0204-0000-19-296-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Summarize the key pathophysiologic, pharmacokinetic, and pharmacodynamic differences between adult and pediatric patients that affect anticoagulation requirements.
  • Analyze the potential benefits and limitations of using direct oral anticoagulants (DOACs) in pediatric patients.
  • Identify appropriate anticoagulation reversal agents for pediatric patients.
  • Evaluate recent literature on addressing anticoagulation strategies for pediatric patients receiving extracorporeal membrane oxygenation (ECMO) therapy.

This activity is approved for Board Certified Pediatric Pharmacist (BCPPS) recertification credit.

Planners, Presenters, and Reviewers 

Full Faculty Bios

James Gilmore, Pharm.D., BCCCP, BCPS
Pharmacy Manager, Critical Care & Emergency Department
Cedars-Sinai
Los Angeles, California 
Kaitlin M. Hughes, Pharm.D., BCPPS
Clinical Pharmacist Pediatric Intensive Care
Riley Hospital for Children at IU Health
Indianapolis, Indiana
Jamie L. Miller, Pharm.D., BCPPS, BCPS
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma
Steve A. Martin, Pharm.D., BCPPS
Pediatric Operations Manager and Clinical Pharmacy Specialist in Pediatric Cardiology
Levine Children’s Hospital
Carolinas Medical Center
Charlotte, North Carolina
Keliana O'Mara, Pharm.D.
NICU Clinical Pharmacy Specialist
UF Health
Gainesville, Florida
Jessica Otero, Pharm.D.
Clinical Pharmacist: Critical Care and Anticoagulation
Seattle Children’s Hospital
Seattle, Washington

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Adjunct Associate
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma
Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Clinical Pharmacy Practice Manager
Brigham and Women's Hospital
Foxboro, Massachusetts
Jennifer L. Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Holly L. Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, Pharm.D.
Robert Tremmel, Pharm.D.

Suzan Asfour, MSc, BCPPS, BCNSP
Daniel Baker, Pharm.D., BCPS, BCCCP, BCIDP
Meghan Baldo, Pharm.D, BCPPS
Karen Brodbeck, R.Ph., BCPPS
Brian Brown, Pharm.D., BCPS, BCPPS
Darlene Chaykosky , Pharm.D., BCPS, BCCCP
Rou-Yee Chenhsu, Pharm.D, BCPS, BCPPS
Jesse Cramer, Pharm.D., BCPPS
Kelli Crowley, Pharm.D., BCPS, BCPPS
Debra Determan, Pharm.D. BCPPS
Tuong Diep, Pharm. D, BCPS, BCCCP, BCIDP
Darrin Dillingham, Pharm.D., BCPPS
Lea Eiland, Pharm.D., BCPS, BCPPS, FASHP, FPPA
Alexandra Fife, Pharm.D., BCPPS
Gina Gries, Pharm.D., BCPS, BCPPS
Sarah Hale, Pharm.D., BCPPS
Aaron Harthan, Pharm.D., BCPPs
Karen Kovey, Pharm.D., BCPS, BCPPS
Emily Kurzen, Pharm.D., BCPPS
Kimberley Limouze, Pharm.D., BCPS, BCCCP
Susan Norman, Pharm.D., BCPPS, BCPS
Michael Raschka, Pharm.D., BCPPS
Justin Sheets, BCPPS
Laura Siemianowski, Pharm.D., BCPS, BCCCP
Tara Smith, Pharm D, BCPPS
Zachary Smith, Pharm.D., BCPS, BCCCP
Amy Snowden, Pharm.D., BCPPS
Shannon Song, Pharm.D., BCPPS
Janesha Thomas, Pharm.D., BCPPS
Julie Tremblay, BCPPS
Antonia Vilella, Pharm.D., BCCCP, BCPS
Matthew Wanat, Pharm.D., BCPS, BCCCP, FCCM
Jessica Whalen, Pharm.D., BCCCP, BCPS
Sharon Wilson, Pharm.D., BCCCP, BCPS
Amy Wojciechowski, Pharm.D., BCPS, BCIDP, BCCCP, CIC
Jennifer Young, Pharm.D., BCPPS

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

All planners, presenters, and reviewers of this session report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of audio/ video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP.